

## Appointment of Ms Janine Rolfe to the Cynata Board of Directors

**Melbourne, Australia; 30 August 2022:** Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the appointment of Ms Janine Rolfe as an independent Non-Executive Director, effective 1 September 2022.

### Ms Rolfe said:

*“I am delighted to be joining Cynata at a time when the Company’s robust clinical product development pipeline is advancing rapidly, and the Company’s commercial and strategic opportunities continue to progress. Cynata is the global leader in the development of induced pluripotent stem cell (iPSC) derived cell therapy products and I am very excited to be involved in the next stage of the Company’s growth.”*

Ms Rolfe brings to the Cynata Board over two decades’ legal, governance and management experience across multiple sectors, including highly regulated industries and complex global businesses. Before recently transitioning as a professional non-executive director, Ms Rolfe’s last executive position was General Counsel & Company Secretary of Link Administration Holdings Limited (Link Group). Prior to that, Ms Rolfe founded Company Matters Pty Limited and worked both in-house (Qantas Airways Limited) and in private practice (Mallesons Stephen Jaques, now King & Wood Mallesons), across a diverse and distinguished career.

### Dr Geoff Brooke, Cynata’s Chairman, said:

*“Cynata continues to build a team with proven leadership capabilities and with Janine joining the Board of Directors we welcome a new skill set and contemporary outlook. Janine’s extensive experience in M&A, governance and growth businesses will add a new depth of talent to the Company at a very exciting time in our maturation. We welcome Janine to the Board and look forward to her contributions toward the advancement of Cynata and the flourishing Cymerus™ product pipeline.”*

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

**CONTACTS:** Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Lauren Nowak, Media Contact, +61 (0)400 434 299, [littlebitdealconsulting@gmail.com](mailto:littlebitdealconsulting@gmail.com)

### About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Planning for a Phase 2 clinical trial in GvHD under a cleared US FDA IND is presently underway. Clinical trials of Cymerus products in osteoarthritis (Phase 3) and diabetic foot ulcers (DFU) are currently ongoing. In addition, Cynata has demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

**Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.**